In the rapidly evolving biotechnology sector, efficient and sterile sampling from bioreactors is crucial for maintaining product quality and process integrity. Traditional manual sampling methods are often labor-intensive and susceptible to contamination, posing significant challenges in large-scale biopharmaceutical production. Recognizing these hurdles, Lonza Pharma & Biotech developed the Modular Automated Sampling Technology (MAST) platform, a groundbreaking solution that automates sterile sampling, enhancing both efficiency and reliability in bioprocessing.
In 2022, Merck KGaA acquired the MAST platform, integrating it into their bioprocessing portfolio to further advance automated solutions and drive efficiency in biopharmaceutical manufacturing.
The Challenge: Manual Sampling Limitations
Biopharmaceutical manufacturing involves complex processes where maintaining sterility and precision is paramount. Manual sampling from bioreactors presents several challenges:
- Labor-Intensive Processes: Frequent manual sampling requires significant human resources, increasing operational costs.
- Risk of Contamination: Each manual intervention introduces potential contamination risks, compromising product quality.
- Inconsistent Sampling: Variability in manual techniques can lead to inconsistent sample quality, affecting data reliability.
These issues highlight the need for an automated solution to ensure consistent, sterile, and efficient sampling in biopharmaceutical production.
The Solution: Modular Automated Sampling Technology (MAST)
Lonza’s MAST platform addresses these challenges through a combination of automation and modularity:
- Automated Sterile Sampling:
- The MAST platform enables the collection of up to 10 sterile samples from various sources, significantly reducing manual interventions and contamination risks.
- Modular Design for Scalability:
- The modular nature of MAST allows customization for specific bioprocess needs, facilitating integration with existing systems and supporting seamless scaling for future expansions.
- Enhanced Data Integration:
- The platform interfaces seamlessly with multiple analytical devices, streamlining data collection and analysis for real-time process monitoring.
By automating the sampling process, MAST enhances operational efficiency and maintains the stringent sterility standards critical for biopharmaceutical manufacturing.
Results and Benefits
The implementation of the MAST platform has yielded significant advantages for biopharmaceutical production:
- Increased Efficiency: Automation reduces manual labor, freeing skilled personnel to focus on higher-value tasks, thereby improving overall productivity.
- Enhanced Sterility: Automated sampling minimizes contamination risks, ensuring higher product quality and compliance with regulatory standards.
- Scalability: The modular design supports easy adaptation to varying production scales, accommodating both small-scale and large-scale manufacturing needs.
- Cost Savings: Reduced labor costs and minimized risks of contamination-related waste contribute to overall operational savings, enhancing profitability.
These benefits illustrate how MAST transforms biopharmaceutical manufacturing by combining automation with flexibility, resulting in more reliable and efficient production processes.
Conclusion
Lonza’s MAST platform exemplifies the innovation required to address critical challenges in biopharmaceutical manufacturing. By enhancing sampling efficiency and maintaining sterility, MAST improved product quality and offered scalable, cost-effective advantages. Now part of Merck KGaA’s portfolio, the platform is poised to drive further advancements in automated sampling technology, setting a new standard for biopharmaceutical production.
This case highlights the importance of integrating advanced, modular technologies to meet the demands of an evolving biotech industry, paving the way for more sustainable, efficient, and reliable manufacturing practices.
Further Reading
Lonza – Enabling a Healthier World
Merck Acquires MAST
Modular Automated Technology Allows Multiple Bioreactor Sterile Sampling
MilliporeSigma acquires automated bioreactor-sampling platform from Lonza